From Type 2 Diabetes Mellitus To Diabetic Cardiomyopathy – A Systematic Review On The Role Of MicroRNA

PURPOSE OF REVIEW: Diabetes mellitus (DM) is a growing global health concern, and diabetic cardiomyopathy (DCM) affects up to 12% of individuals with diabetes, leading to myocardial hypertrophy, ventricular remodeling, and contractile dysfunction, ultimately progressing to heart failure (HF). This review explores the role of microRNAs (miRNAs) in DCM development and their potential as diagnostic and therapeutic biomarkers. RECENT FINDINGS: MicroRNAs, short single-stranded non-coding RNAs, are key regulators of various pathophysiological processes in DCM. By modulating gene expression, they influence critical signaling pathways involved in inflammation, apoptosis, pyroptosis, oxidative stress, and fibrosis, all of which contribute to DCM progression. Emerging research suggests that miRNAs could serve as early-stage biomarkers for asymptomatic DCM and may offer novel therapeutic targets. This systematic review compiles current findings from both animal and human studies on the role of miRNAs in DCM. It highlights their potential in the early diagnosis and treatment of DCM, underscoring the need for further research to translate these insights into clinical applications.